BiosciNews

This study utilised a database of over 900 neuroendocrine patients from a single centre to assess their presenting symptoms, disease-free survival and overall survival levels. Overall, they found that while the majority of patients are diagnosed relatively soon after their initial symptoms develop, there are notable exceptions to this. Chromogranin A (CGA) levels proved to be a significant predictor of patient survival, regardless of tumour type.

Ter-Minassian et al. Clinical presentation, recurrence, and survival in patients with neuroendocrine tumors: results from a prospective institutional database. Endocrine-Related Cancer, published online 14 January 2013 (DOI: 10.1530/ERC-12-0340).

The full abstract can be accessed here.

Clinical presentation, recurrence, and survival in patients with neuroendocrine tumors: results from a prospective institutional database

Share this story

Top stories

Most read